原发性肝癌患者外周血CD4+T、CD8+T、Tc17、Th17和Treg淋巴细胞的变化及其意义*

doi:10.3969/j.issn.1672-5069.2022.02.026

Abstract

Abstract: Objective The aim of this study was to investigate the implication of peripheral CD4+T, CD8+T, Tc17, Th17 and Treg lymphocyte changes in patients with primary liver cancer (PLC). Methods 83 patients with PLC (BCLC stage A in 25, stage B in 23, stage C in 18, and stage D in 17) and 35 healthy individuals were recruited in our hospital between June 2018 and December 2019, and the percentages of peripheral blood CD4+T, CD8+T, Tc17 (CD8+ IL-17), Th17(CD4+ IL-17) and CD4+CD25+CD45RA+ Treg lymphocytes were detected by flow cytometry. Results The percentage of peripheral blood CD4+ T lymphocytes in patients with PLC was (32.8±8.5)%, significantly lower than [(43.3±7.4)%, P ＜0.05], and the ratio of CD4+/CD8 + cells were (0.9±0.3), also significantly lower than [(1.2±0.1), P ＜0.05] in healthy control; the percentages of peripheral blood Treg cell[(6.4±0.9)% vs. (3.0±0.1)%], Th17 cell [(5.0±1.1)% vs. (3.1±1.5)%] and Tc17 cell [(2.3±0.4)% vs. (1.0±0.2)%] were all significantly increased as compared to those in the control (all P＜0.05); the percentage of CD4+CD25+CD45RA+ Treg cell in patients with BCLC stage C/D increased greatly compared to that in patients with stage A/B [(7.6±0.4) % vs.(5.3±0.5)%, P＜0.001], the percentages of Th17(CD4+ IL-17) cell and Tc17(CD8+ IL-17) cell also increased greatly compared to in patients with stage A/B[(6.9±1.1)% vs. (5.4±0.6)%, P ＜0.01 and (2.8±0.6)% vs. (1.6±0.4)%, P＜0.01]. Conclusion There is an immune imbalance of peripheral blood lymphocyte subsets in patients with PLC, which might hint the immunotherapy targeting at regulating T lymphocyte imbalance necessary in this setting.

Key words: Hepatoma, CD4+T/CD8+T lymphocytes, TC17 lymphocytes, Th17/Treg cell ratio

Liu Huimin, Liu Xiaoli, Wang Xinhui, et al. Implication of peripheral CD4+T, CD8+T, Tc17, Th17 and Treg lymphocyte changes in patients with primary liver cancer[J]. Journal of Practical Hepatology, 2022, 25(2): 255-258.

References

[1] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗规范(2019年版). 传染病信息, 2020,33(6):481-500.
[2] 李亚敏, 王瑞婷, 王瑛瑛. 冷循环射频消融术治疗原发性肝癌患者疗效及外周血Treg细胞的变化观察. 实用肝脏病杂志, 2021,24(1):123-126.
[3] 乔敏, 赵一鉴, 张建巧, 等. TACE联合射频消融治疗原发性肝癌患者疗效研究. 实用肝脏病杂志, 2021,24(1):119-122.
[4] 刘奇, 郝吉庆. 免疫联合治疗肝细胞癌研究进展. 实用肝脏病杂志, 2021,24(1):7-9.
[5] Avritscher R, Jo N, Polak U, et al. Hepatic arterial bland embolization increases Th17 cell Iifiltration in a syngeneic rat model of hepatocellular carcinoma. Cardiovasc Intervent Radiol, 2020,43(2):311-321.
[6] Hasan I, Gani R A, Lesmana L A, et al. The association between peripheral Th17, Th1, IL-17, and IFN-gamma levels and TACE response in patients with unresectable hepatocellular carcinoma with or without cirrhosis. Acta Med Indones, 2020,52(4):326-333.
[7] Peng Y, Yang J, Guo D, et al. Sufentanil postoperative analgesia reduce the increase of T helper 17 (Th17) cells and FoxP3(+) regulatory T (Treg) cells in rat hepatocellular carcinoma surgical model: A randomised animal study. BMC Anesthesiol, 2020,20(1):212.
[8] 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版). 中华消化外科杂志, 2017,16(7):635-647.
[9] Alejandro F, María E R, Carlos R D L, et al. Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis, 2010,30(1):61-74.
[10] Ringelhan M, Pfister D, O'Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol, 2018,19(3):222-232.
[11] Jiang Y, Han Q J, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol, 2019,25(25):3151-3167.
[12] Huber M, Heink S, Grothe H, et al. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity. Eur J Immunol, 2009,39(7):1716-1725.
[13] Kuang D M, Peng C, Zhao Q, et al. Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol, 2010,185(3):1544-1549.
[14] Ma S, Cheng Q, Cai Y, et al. IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res, 2014,74(7):1969-1982.
[15] Mou H, Wu S, Zhao G, et al. Changes of Th17/Treg ratio in the transition of chronic hepatitis B to liver cirrhosis and correlations with liver function and inflammation. Exp Ther Med, 2019,17(4):2963-2968.
[16] Yao S X, Zhang G S, Cao H X, et al. Correlation between microRNA-21 and expression of Th17 and Treg cells in microenvironment of rats with hepatocellular carcinoma. Asian Pac J Trop Med, 2015,8(9):762-765.
[17] Li J, Lau G, Chen L, et al. Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS One, 2012,7(9):e46264.
[18] Cho H J, Kim S S, Nam J S, et al. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib. Cytokine, 2017,95:118-125.
[19] Chen X, Du Y, Huang Z. CD4+CD25+ Treg derived from hepatocellular carcinoma mice inhibits tumor immunity. Immunol Lett, 2012,148(1):83-89.
[20] Takata Y, Nakamoto Y, Nakada A, et al. Frequency of CD45RO+ subset in CD4+CD25(high) regulatory T cells associated with progression of hepatocellular carcinoma. Cancer Lett, 2011,307(2):165-173.
[21] Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma. Cancer Lett, 2020,470:8-17.

Implication of peripheral CD4+T, CD8+T, Tc17, Th17 and Treg lymphocyte changes in patients with primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Chan, Shen Changqing, Wu Xiaoqiong, et al. Efficacy and safety of epirubicin drug-eluting beads-transcatheter arterial chemoembolization in the treatment of patients with unresectable primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(2): 259-262.
[2]	Wang Xinran, Jiang Yandong, Zhang Meng. Local control of tumors in patients with hepatocellular carcinoma receiving ultrasound-guided intratumorous125I radioactive particle implantation [J]. Journal of Practical Hepatology, 2022, 25(2): 263-266.
[3]	Wang Lianshuang, Zhang Yao, Shan Tao, et al. Ultrasonographic feature and prognosis of patients with hepatocellular carcinaoma and cardiac metastases: Analysis of 19 cases [J]. Journal of Practical Hepatology, 2022, 25(2): 271-274.
[4]	Li Huan, Li Yang, Du Juan, et al. Cancerous expression and functional relations of glypican3 and sonic Hedgehog proteins in patients with hepatocellular carcinoma and in hepatoma cell lines in vitro [J]. Journal of Practical Hepatology, 2022, 25(1): 83-87.
[5]	Peng Nan, Ma Aizhen, Shi Zhan, et al. Application of CT 3D reconstruction in the evaluation of resectability of massive intrahepatic tumors in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(1): 96-99.
[6]	Zhou Yan, Li Guoping, Deng Jun, et al. Efficacy of thymosin alpha 1 in maintained treatment of patients with primary liver cancer after radiofrequency ablation [J]. Journal of Practical Hepatology, 2021, 24(6): 907-910.
[7]	Zhou Zheng, Liu Wei. Contrast-enhanced ultrasound features of hepatic hemangioma, hepatocellular carcinoma and hepatic angiomyolipoma [J]. Journal of Practical Hepatology, 2021, 24(6): 911-914.
[8]	Zhao Pengfei, Zu Hongmei, Xin Xiaoen, et al. Logistic regression analysis of risk factors in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(6): 927-929.
[9]	Peng Guangming, Ge Shang, Jin Guiyin. Image quality of adaptive statistical iterative reconstruction under low tube voltage of CT scan in diagnosis of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(5): 737-740.
[10]	Yu Lei, Sun Chao, Zhang Manxu. Regulation of intestinal floras and their metabolism functions by ganoderma lucidum plysaceharide in mice with HepG2 cell-induced implanted cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 476-479.
[11]	Chen Wei, Wei Tao, Yang Lan, et al. Expression of NLRP3 inflammasome in cancerous tissues of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 544-547.
[12]	Liu Yongchang, Zhao Diantang, Sun Qifeng, et al. Application of indocyanine green fluorescence navigationand three-dimensional visualization in laparoscopic precision surgery for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 561-564.
[13]	Gao Jinlong, Wang Haifeng, Li Na, et al. Target delineation accuracy of tumors for radiotherapy based on MR-T2 image in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(4): 565-568.
[14]	Wang Qunxian, Wang Yunchuan, Chen Youying. Effect of sevoflurane inhalation at different times during anesthesia in patients with primary liver cancer undergoing partial hepatectomy [J]. Journal of Practical Hepatology, 2021, 24(4): 597-599.
[15]	An Xiquan, Li Yan, Menggen Caicike. Clinical observation of tenofovir and sorafenib in the treatment of patients with hepatitis B associated advanced primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 600-602.